CA2505964A1 - Pharmaceutical compositions and dosage forms of thalidomide - Google Patents

Pharmaceutical compositions and dosage forms of thalidomide Download PDF

Info

Publication number
CA2505964A1
CA2505964A1 CA002505964A CA2505964A CA2505964A1 CA 2505964 A1 CA2505964 A1 CA 2505964A1 CA 002505964 A CA002505964 A CA 002505964A CA 2505964 A CA2505964 A CA 2505964A CA 2505964 A1 CA2505964 A1 CA 2505964A1
Authority
CA
Canada
Prior art keywords
dosage forms
thalidomide
pharmaceutical compositions
disclosed
clathrates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002505964A
Other languages
French (fr)
Other versions
CA2505964C (en
Inventor
Paul D'angio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326306&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2505964(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2505964A1 publication Critical patent/CA2505964A1/en
Application granted granted Critical
Publication of CA2505964C publication Critical patent/CA2505964C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers

Abstract

Pharmaceutical compositions and single unit dosage forms of thalidomide and pharmaceutically acceptable prodrugs, salts, solvates, hydrates, or clathrates are disclosed. Also disclosed are methods of treating and preventing diseases and conditions such as, but not limited to, leprosy, chronic graft-vs-host disease, rheumatoid arthritis, sarcoidosis, an inflammatory condition, inflammatory bowel disease, and cancer using the novel dosage forms disclosed herein.
CA002505964A 2002-11-14 2003-11-13 Pharmaceutical compositions and dosage forms of thalidomide Expired - Lifetime CA2505964C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42601602P 2002-11-14 2002-11-14
US60/426,016 2002-11-14
PCT/US2003/036620 WO2004045579A2 (en) 2002-11-14 2003-11-13 Pharmaceutical compositions and dosage forms of thalidomide

Publications (2)

Publication Number Publication Date
CA2505964A1 true CA2505964A1 (en) 2004-06-03
CA2505964C CA2505964C (en) 2009-07-28

Family

ID=32326306

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002505964A Expired - Lifetime CA2505964C (en) 2002-11-14 2003-11-13 Pharmaceutical compositions and dosage forms of thalidomide

Country Status (19)

Country Link
US (1) US7230012B2 (en)
EP (2) EP2277512A3 (en)
JP (2) JP5269280B2 (en)
KR (1) KR100671366B1 (en)
CN (2) CN101816626A (en)
AU (2) AU2003290982C1 (en)
BR (1) BR0316240A (en)
CA (1) CA2505964C (en)
DK (1) DK1562556T3 (en)
ES (1) ES2403142T3 (en)
HK (1) HK1088543A1 (en)
IL (1) IL168585A (en)
MX (1) MXPA05005162A (en)
NZ (1) NZ540545A (en)
PT (1) PT1562556E (en)
SI (1) SI1562556T1 (en)
TW (2) TWI359659B (en)
WO (1) WO2004045579A2 (en)
ZA (1) ZA200503927B (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7230012B2 (en) * 2002-11-14 2007-06-12 Celgene Corporation Pharmaceutical compositions and dosage forms of thalidomide
US7838029B1 (en) * 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
US20110008327A1 (en) 2004-03-29 2011-01-13 Cheng Jin Q Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
WO2005094322A2 (en) 2004-03-29 2005-10-13 University Of South Florida Effective treatment of tumors and cancer with triciribine and related compounds
US20100009928A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
US20100173864A1 (en) 2004-03-29 2010-07-08 Cheng Jin Q Compositions including triciribine and one or more platinum compounds and methods of use thereof
US20100028339A1 (en) 2004-03-29 2010-02-04 Cheng Jin Q Compositions including triciribine and trastuzumab and methods of use thereof
US7534381B2 (en) * 2005-09-14 2009-05-19 Isp Investments Inc. Process and apparatus for forming agglomerates of a powder composition of an active and binder
CN1870631B (en) * 2005-11-11 2010-04-14 华为技术有限公司 Gate control method of media gateway
RU2454220C2 (en) * 2006-08-16 2012-06-27 Новартис Аг Method for preparing solid dispersions of high crystalline therapeutic compounds
ES2382756T3 (en) * 2006-11-10 2012-06-13 Alphaptose Gmbh Oral dosage form comprising trisubstituted glycerol compounds
US20090137631A1 (en) * 2007-11-22 2009-05-28 National Yang-Ming University Methods and pharmaceutical compositions for regulation of g- and/or gc-rich nucleic acid expression
TR201905423T4 (en) 2009-05-19 2019-05-21 Celgene Corp Formulations of 4-amino-2- (2,6-dioxopiperidin-3-yl) isindoline-1,3-dione
KR101369936B1 (en) * 2011-12-28 2014-03-06 연세대학교 산학협력단 Pharmaceutical composition for treating lupus nephritis comprising thalidomide
JP5087182B1 (en) 2012-06-13 2012-11-28 クリニプロ株式会社 Method for producing inhalable powder
AU2015210999A1 (en) 2014-01-29 2016-07-21 Otsuka Pharmaceutical Co., Ltd. Device-based risk management of a therapeutic
CN106137986B (en) * 2015-03-09 2019-04-16 常州制药厂有限公司 A kind of Thalidomide piece and preparation method thereof
CN106138052B (en) * 2015-04-16 2020-02-21 欣凯医药化工中间体（上海）有限公司 Thalidomide preparation and preparation method thereof
JP2020533383A (en) 2017-09-14 2020-11-19 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Combination treatment of cancer
WO2019099868A2 (en) 2017-11-16 2019-05-23 C4 Therapeutics, Inc. Degraders and degrons for targeted protein degradation
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
JP2021519337A (en) 2018-03-26 2021-08-10 シー４ セラピューティクス， インコーポレイテッド Cereblon binder for the degradation of Ikaras
WO2019204354A1 (en) 2018-04-16 2019-10-24 C4 Therapeutics, Inc. Spirocyclic compounds
WO2020051235A1 (en) 2018-09-04 2020-03-12 C4 Therapeutics, Inc. Compounds for the degradation of brd9 or mth1
KR20200054046A (en) 2018-11-09 2020-05-19 한국화학연구원 Novel piperidine-2,6-dione derivatives and use thereof
CN113453679A (en) 2018-12-20 2021-09-28 C4医药公司 Targeted protein degradation
EP3935050A4 (en) 2019-03-06 2023-01-04 C4 Therapeutics, Inc. Heterocyclic compounds for medical treatment
KR20230068335A (en) 2021-11-09 2023-05-17 한국화학연구원 Glutarimide moiety based isoindolinone derivatives and use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1531492A (en) 1991-02-14 1992-09-15 Rockefeller University, The Method for controlling abnormal concentration tnf alpha in human tissues
US6228879B1 (en) 1997-10-16 2001-05-08 The Children's Medical Center Methods and compositions for inhibition of angiogenesis
US6114355A (en) 1993-03-01 2000-09-05 D'amato; Robert Methods and compositions for inhibition of angiogenesis
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US5405855A (en) 1993-12-23 1995-04-11 Andrulis Pharmaceuticals Corp. Treatment of insulin resistant diabetes with thalidomine
US5434170A (en) 1993-12-23 1995-07-18 Andrulis Pharmaceuticals Corp. Method for treating neurocognitive disorders
US6001828A (en) 1995-06-05 1999-12-14 Andrulis, Jr.; Peter Use of tumor factor inhibitors together with antiviral agents and therapeutic compositions thereof against HIV infection
US5731325A (en) 1995-06-06 1998-03-24 Andrulis Pharmaceuticals Corp. Treatment of melanomas with thalidomide alone or in combination with other anti-melanoma agents
US5643915A (en) * 1995-06-06 1997-07-01 Andrulis Pharmaceuticals Corp. Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies
US5654312A (en) 1995-06-07 1997-08-05 Andrulis Pharmaceuticals Treatment of inflammatory and/or autoimmune dermatoses with thalidomide alone or in combination with other agents
DE69740095D1 (en) 1996-11-05 2011-02-17 Childrens Medical Center Thalidomide and dexamethasone for the treatment of tumors
CA2319872C (en) * 2000-02-02 2012-06-19 Chun-Ying Huang Pharmaceutical composition for the treatment of hepatocellular carcinoma
CN1420776A (en) * 2000-03-31 2003-05-28 塞尔基因公司 Inhibition of cyclooxygenase-2 activity
DK1286671T3 (en) * 2000-05-15 2006-07-17 Celgene Corp Compositions for the treatment of colorectal cancers containing thalidomide and irinotecan
WO2003080048A1 (en) * 2002-03-20 2003-10-02 Celgene Corporation (-)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7230012B2 (en) * 2002-11-14 2007-06-12 Celgene Corporation Pharmaceutical compositions and dosage forms of thalidomide

Also Published As

Publication number Publication date
JP2009215310A (en) 2009-09-24
ES2403142T3 (en) 2013-05-14
EP1562556B1 (en) 2013-01-23
JP5269280B2 (en) 2013-08-21
KR100671366B1 (en) 2007-01-19
TW200731973A (en) 2007-09-01
WO2004045579A3 (en) 2004-09-10
TW200505449A (en) 2005-02-16
CA2505964C (en) 2009-07-28
HK1088543A1 (en) 2006-11-10
TWI359659B (en) 2012-03-11
CN1738607A (en) 2006-02-22
AU2003290982B2 (en) 2009-07-02
JP4927905B2 (en) 2012-05-09
BR0316240A (en) 2005-10-11
IL168585A (en) 2015-01-29
SI1562556T1 (en) 2013-05-31
DK1562556T3 (en) 2013-03-25
ZA200503927B (en) 2006-08-30
EP2277512A2 (en) 2011-01-26
EP2277512A3 (en) 2012-07-04
JP2006508983A (en) 2006-03-16
KR20050086624A (en) 2005-08-30
EP1562556A2 (en) 2005-08-17
PT1562556E (en) 2013-04-23
AU2003290982A1 (en) 2004-06-15
WO2004045579A2 (en) 2004-06-03
NZ540545A (en) 2007-10-26
TWI377062B (en) 2012-11-21
US20040138263A1 (en) 2004-07-15
US7230012B2 (en) 2007-06-12
CN101816626A (en) 2010-09-01
AU2010201931A1 (en) 2010-07-01
MXPA05005162A (en) 2005-07-22
CN1738607B (en) 2014-05-14
AU2003290982C1 (en) 2010-10-07

Similar Documents

Publication Publication Date Title
CA2505964A1 (en) Pharmaceutical compositions and dosage forms of thalidomide
MXPA04003439A (en) 3,4-di-substituted maleimide compounds as cxc-chemokine receptor antagonists.
MXPA05010958A (en) Indazole derivatives as jnk inhibitors.
MXPA04006555A (en) 3,4-di-substituted pyridazinediones as cxc chemokine receptor antagonists.
MY148125A (en) Compounds
AU3664401A (en) Platelet adp receptor inhibitors
EP2260835A3 (en) Composition for proteasome inhibition
HK1062677A1 (en) 17Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
MA26769A1 (en) THIOAMIDE DERIVATIVES.
HRP20070020T3 (en) 1-(2h-pyrazol-3-yl)-3- 4-[1-(benzoyl)-piperidin-4-ylmethyl]-phenyl -urea derivatives and related compounds as inhibitors of p38 kinase and/or tnf inhibitors for the treatment of inflammations
IL169439A0 (en) Fluoroalkoxy-substituted 1,3 - dihydro-isoindolyl compounds and their pharmaceutical uses
TW200736196A (en) 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
WO2001035950A3 (en) Benzamide therapeutics and methods for treating inflammatory bowel disease
CY1108625T1 (en) PHARMACEUTICAL COMPOSITIONS FOR ADMINISTRATION FROM US ORAL OR PRODUCERS
WO2003053359A3 (en) 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
MX2008001606A (en) Substituted piperazines as metabotropic glutamate receptor antagonists.
RS20050470A (en) Solid drug for oral use
WO2003106450A8 (en) Phenylaminopyrimidines and their use as rho-kinase inhibitors
NO20071399L (en) VLA-4 antagonists
MXPA05012705A (en) A pharmaceutical composition comprising a p2x7.
UA92009C2 (en) 4-PHENYL-5-0X0-l,4,5,6,7,8-HEXAHYDR0QЛIN0LINE DERIVATIVES AS MEDICAMENTS FOR THE TREATMENT OF INFERTILITY
MX2008001608A (en) Acetylenic piperazines as metabotropic glutamate receptor antagonists.
WO2008005352A3 (en) Solid dose formulations of a thrombin receptor antagonist
DE60006542D1 (en) CONNECTIONS THAT INHIBIT TRYPTASE ACTIVITY
DE69917005D1 (en) SUBSTITUTED PYRROLOBENZIMIDAZOLE DERIVATIVES FOR ANTI-INFLAMMATION

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20231114